Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review

  • ID: 4395088
  • SWOT Analysis
  • 46 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Adaptimmune Ltd
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Juno Therapeutics Inc
  • Novartis AG
  • Pfizer Inc
  • MORE
Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidate, LN-144 is an autologous, ready-to-infuse cell therapy. The product is an adoptive cell therapy using TIL technology and is being investigated in Phase II trials for treating patients with metastatic melanoma, recurrent and metastatic squamous cell carcinoma of the neck and head and recurrent and metastatic or persistent cervical cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

Iovance Biotherapeutics Inc Key Recent Developments

Sep 07,2017: Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center
Aug 31,2017: Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications
Aug 08,2017: Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer
Aug 01,2017: Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results
Jun 27,2017: Lion Biotechnologies Changes Name to Iovance Biotherapeutics

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adaptimmune Ltd
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Juno Therapeutics Inc
  • Novartis AG
  • Pfizer Inc
  • MORE
Section 1 - About the Company
  • Iovance Biotherapeutics Inc - Key Facts
  • Iovance Biotherapeutics Inc - Key Employees
  • Iovance Biotherapeutics Inc - Key Employee Biographies
  • Iovance Biotherapeutics Inc - Major Products and Services
  • Iovance Biotherapeutics Inc - History
  • Iovance Biotherapeutics Inc - Company Statement
  • Iovance Biotherapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Iovance Biotherapeutics Inc - Business Description
  • Iovance Biotherapeutics Inc - Corporate Strategy
  • Iovance Biotherapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Iovance Biotherapeutics Inc - Strengths
  • Iovance Biotherapeutics Inc - Weaknesses
  • Iovance Biotherapeutics Inc - Opportunities
  • Iovance Biotherapeutics Inc - Threats
  • Iovance Biotherapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Iovance Biotherapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 07, 2017: Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center
  • Aug 31, 2017: Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications
  • Aug 08, 2017: Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer
  • Aug 01, 2017: Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results
  • Jun 27, 2017: Lion Biotechnologies Changes Name to Iovance Biotherapeutics
  • May 25, 2017: Lion Biotechnologies Announces Departure of Chief Financial Officer
  • May 01, 2017: Lion Biotechnologies Reports First Quarter 2017 Financial Results
  • Apr 26, 2017: Lion Biotechnologies Announces New Manufacturing Services Agreement with PharmaCell
  • Mar 07, 2017: Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update
  • Nov 28, 2016: Lion Biotechnologies Announces New Manufacturing Services Agreement with WuXi AppTec
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Iovance Biotherapeutics Inc, Key Facts
  • Iovance Biotherapeutics Inc, Key Employees
  • Iovance Biotherapeutics Inc, Key Employee Biographies
  • Iovance Biotherapeutics Inc, Major Products and Services
  • Iovance Biotherapeutics Inc, History
  • Iovance Biotherapeutics Inc, Other Locations
  • Iovance Biotherapeutics Inc, Subsidiaries
  • Iovance Biotherapeutics Inc, Key Competitors
  • Iovance Biotherapeutics Inc, Ratios based on current share price
  • Iovance Biotherapeutics Inc, Annual Ratios
  • Iovance Biotherapeutics Inc, Annual Ratios (Cont...1)
  • Iovance Biotherapeutics Inc, Interim Ratios
  • Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Iovance Biotherapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Iovance Biotherapeutics Inc, Performance Chart (2012 - 2016)
  • Iovance Biotherapeutics Inc, Ratio Charts
  • Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • Novartis AG
  • Juno Therapeutics Inc
  • GlaxoSmithKline Plc
  • Bristol-Myers Squibb Company
  • Amgen Inc
  • Adaptimmune Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll